close× Call Us 1(844) 401-0111

Recent Memory and Aging Program News

See the latest news about Butler Hospital's Memory & Aging Program and how they are working towards a future without Alzheimer's disease through clinical research studies.

Providence Journal: Surprise turnaround finds Alzheimer's treatment may work
WPRI 12 News: Potential game-changing Alzheimer's drug studied at Butler Hospital

Aducanumab Could Become First Treatment to Slow Alzheimer's Progression
Biogen, maker of the investigational drug aducanumab, announced Tuesday morning that it will seek review of the drug by the US Food and Drug Administration (FDA) in early 2020. It has been 16 years since the last drug received approval for Alzheimer's. If approved, it will become the first drug that actually tackles the disease itself.

Providence Journal: Brown to share $53 million grant advance alzheimer's, dementia research
A five year, National Institute on Aging $53.4-million federal grant to Brown University and Boston-based Hebrew SeniorLife could lead to improved health care and quality of life for people living with Alzheimer’s disease and related dementias, as well as their caregivers. This is the largest federal grant in Brown history and will support a research incubator called the “NIA Imbedded Pragmatic AD/ADRD Clinical Trials (IMPACT) Collaboratory.” Unlike other Alzheimer’s research, which emphasizes pharmaceuticals, the Brown/Hebrew SeniorLife incubator will investigate non-drug interventions.

Cranston Herald: Free Registries to Better Understand, Treat Alzheimer’s
There are several free registries in Rhode Island that connect residents to local clinical research opportunities. Butler Hospital’s Memory and Aging Program has a prevention registry for people between the ages of 40-85 interested in learning more about enrolling studies that range from prevention and early AD to new brain scans. They have a goal to sign up 2,020 participants by 2020. For more information go to

GoLocalProv: Leading Alzheimer's Researcher at Warren Alpert Medical School Addresses RI's role in fighting AD
Dr. Stephen Salloway at The Warren Alpert Medical School at Brown University called Alzheimer’s disease the “health crisis of our time” in his appearance on "Smart Health" on GoLocal LIVE — and urged people to consider taking part in the Butler Alzheimer's Prevention Registry, whose goals is to get to 2,020 participants by 2020.

Chronicle, WCVB 5: Joining the Citizen Army
Anthony Everett takes us inside Butler Hospital, one of the top Alzheimer's research centers in the world.
Advancements in diagnosing Alzheimer's
Battling increasing Alzheimer's Rates

Providence Journal:
R.I. Heritage Hall of Fame announces 2019 inductees
Stephen Salloway, Director of Neurology and the Memory and Aging Program at Butler Hospital and Professor of Psychiatry and Human Behavior at the Warren Alpert Medical School of Brown University is one of nine individuals to be inducted into the 2019 R.I. Heritage Hall of Fame.

Providence Journal
: Research finds that brain imaging can improve diagnosis of Alzheimer's disease

Brown University News
: Alzheimer's study finds PET scan affects patient diagnosis, management.
Findings from the national IDEAS study take a step towards understanding how brain imaging to detect Alzheimer's-related plaques affects clinical diagnosis and management of patients with mild cognitive impairment and dementia. The IDEAS study included 1,409 Medicare beneficiaries, 595 clinical sites and 946 dementia specialists. One hundred and thirty participants were from Rhode Island. Brown-affiliated professionals played a major role in this study including lead statistician, Professor Constantine Gatsonis of Brown University's School of Public Health, as well as Dr. Brian Ott of Rhode Island Hospital's Alzheimer's Disease Memory Disorders Center and Dr. Stephen Salloway of Butler's Memory and Aging Program. Dr. Salloway helped plan the initial study and also was senior author for the pivotal trial that led to approval of flutemetemol, one of the amyloid tracers used in the IDEAS trial.

St. Louis Post-dispatch
: The heartbreak and heroism of being the X-Men in Alzheimer's disease
Researchers across the world are seeking answers in cases of those with Dominantly Inherited Alzheimer’s Disease (DIAN). Dean DeMoe's mother and three siblings passed away from Dominantly Inherited Alzheimer's disease. The Memory and Aging Program at Butler Hospital is one of 20 sites across the world enrolling participants for this clinical trial. Click here to view the video.

Diagnostics World:
Pushing Past The Stigma: Spinal Taps For Early Alzheimer's Diagnosis
With increased evidence that biological markers for Alzheimer's disease may form decades before symptoms present themselves, researchers are finding ways to detect the disease earlier and with more accuracy. Analyzing cerebrospinal fluid (CSF), a liquid that circulates in the brain and spinal cord, is one way researchers can look for beta-amyloid and tau proteins. New appropriate use criteria (AUC) has been developed to help bring awareness and guide clinicians in determining the best candidates for this procedure. Stephen Salloway, MD, Director of Butler's Memory and Aging Program joins one of his co-authors José Luis Molinuevo, MD, Ph.D., Scientific Director of the Alzheimer Prevention Program at Barcelona Beta Brain Research Center in Spain, to discuss the stigma of lumbar punctures in both countries as well as the importance of early detection. Click here to learn more.

WJAR Ch. 10: Health Check:
New way to diagnose Alzheimer's disease
Dr. Stephen Salloway was part of a group that came out with new guidelines advising physicians to use lumbar punctures or "spinal taps" for people who either have memory loss or have a family history, as a way to diagnose Alzheimer's — getting them into prevention trials sooner rather than later. Click here to learn more.

Providence Journal:
Researcher Helps Pioneer Alzheimer's Diagnostic
With research bringing potential new treatments for Alzheimer's disease, scientists including Butler Hospital's Dr. Stephen P. Salloway have written criteria for the use of lumbar puncture in diagnosing the fatal disorder. Spinal taps, as they are commonly known, may be used in conjunction with PET scans and other diagnostic measures. Click here to learn more.

Eli Lilly:
Lilly Announces Positive Phase 3 Results in Study of Flortaucipir PET
Imaging Agent Eli Lilly and Avid Radiopharmaceuticals, Inc. announced that a Phase 3 study of flortaucipir F 18, a Positron Emission Tomography (PET) imaging agent, met its two primary endpoints, defined as predicting brain tau pathology and predicting Alzheimer's disease diagnosis. The study, referred to as A16, enrolled a total of 156 end-of-life patients with dementia, mild cognitive impairment, or normal cognition who underwent flortaucipir PET imaging. The study met pre-specified endpoints with flortaucipir demonstrating statistically significant sensitivity and specificity for detecting tau pathology. Click here to learn more.

On Pluto: Inside the Mind of Alzheimer's

Join in a discussion and book signing with award-winning investigative reporter and author Greg O'Brien. Diagnosed with early-onset Alzheimer's, O'Brien writes about living with the disease, not dying with it. And he does it with hope, faith, and humor. This is a complimentary event, but registration is required as seating is limited. Click here to register or call the Memory and Aging Program Outreach Team at (401) 455-6402. Click here to learn more.

A promising drug to slow the progression of Alzheimer's was just unveiled
Alzheimer's is one of the deadliest, costliest, and most emotionally draining diseases in this country. Yet we have no drugs to reverse the condition, and the last medicine that came on the market to treat Alzheimer's symptoms was approved some 15 years ago. Click here to learn more.

Associated Press -
Hopes rise again for a drug to slow Alzheimer's disease
Researchers from Biogen and Eisai announced Wednesday afternoon that the Phase 2 study of the investigational medication, BAN2401, showed promising results in removal of amyloid plaque and slowing the process of Alzheimer's disease at the higher dosage. Click here to learn more.

Lowering blood pressure cut risk of memory decline
U.S. study Aggressively lowering blood pressure significantly reduced the risk of mild cognitive impairment and dementia among hypertension patients in a large government-backed clinical trial, U.S. researchers said on Wednesday. Click here to learn more.

Eisai-Biogen to advance Alzheimer's drug, provide fresh hope
Eisai Co Ltd and Biogen Inc will move forward with late-stage clinical trials of their Alzheimer's disease drug, BAN2401, and are working with regulators to design the next studies and gain expedited review as a breakthrough therapy. Click here to learn more.

New York Times -
For Scientists Racing to Cure Alzheimer's, the Math Is Getting Ugly
The task facing Eli Lilly, the giant pharmaceutical company, sounds simple enough: Find 375 people with early Alzheimer's disease for a bold new clinical trial aiming to slow or stop memory loss. There are 5.4 million Alzheimer's patients in the United States. You'd think it would be easy to find that many participants for a trial like this one.But it's not. And the problem has enormous implications for treatment of a disease that terrifies older Americans and has strained families in numbers too great to count. Click here to learn more.

Alzheimer's Association -
First Practice Guidelines for Clinical Evaluation of Alzheimer's Disease and Other Dementias for Primary and Specialty Care
In response to the urgent need for more timely and accurate Alzheimer's Disease diagnosis and improvement in patient care, the Alzheimer's Association has developed 20 recommendations for physicians and NP's. Click here to learn more.

USA Today:
New Alzheimer's drug trial gives researchers optimism
No effective treatment for Alzheimer's is yet in sight, but better diagnostics, deeper scientific understanding and an encouraging drug trial are leading to a positive mood as the largest Alzheimer's research conference of the year that began Sunday in Chicago. Click here to learn more.

AARP Invests $60 Million to Fund Research for Cures to Dementia and Alzheimer's
AARP's Brain Health Fund is investing $60 million in the Dementia Discovery Fund (DDF), which invests in research and development of breakthrough treatments for dementia. This move reflects AARP's ongoing commitment to helping people with dementia and family caregivers, and makes AARP the single largest investor in the DDF. Click here to learn more.

Boston Globe Magazine:
Can this doctor figure out how to stop Alzheimer's before it starts?
Dr. Reisa Sperling, a lead researcher of Alzheimer's disease and the head of the Center for Alzheimer's Research and Treatment at Brigham and Women's Hospital in Boston, talks about her personal and professional mission to find a cure for Alzheimer's Disease. Click here to learn more.

Memory Sunday -
A designated Sunday that provides education on Alzheimer's: prevention, treatment, research, and caregiving.

Memory Sunday, the SECOND SUNDAY IN JUNE, is a designated Sunday, within congregations serving African Americans, that provides education on Alzheimer's: prevention, treatment, research studies and caregiving. To see the video of the June 10th Memory Sunday, that took place at the Berea SDA church in Dorchester, MA please click here:

WJAR Ch. 10 -
Health Check: New method of tackling Alzheimer's disease
There's a possible new way to attack Alzheimer's disease. Dr. Stephen Salloway, Director of Butler Hospital's Memory and Aging Program discusses a trial that is looking at another important part of Alzheimer's disease - the tangles in the brain. Dr. Salloway notes that "over time the buildup of Tau protein causes nerve cells to get smaller and the brain to shrink, causing memory loss. The tangles are made up of Tau protein and that's what this treatment will attack." Click here to learn more.

Providence Journal:
'Swab party' at Brown's 50th reunion will aid research into Alzheimer's disease
In what may be a national first, two members of the Brown University Class of 1968 will sponsor a "swab party" for 50th-reunion classmates who may wish to enroll in research studies aimed at preventing and curing Alzheimer's disease. The event will include a presentation by Brown professor Dr. Stephen P. Salloway, head of Butler Hospital's Memory and Aging Program, and the collection of a DNA sample from the cheeks of volunteers. Click here to learn more.

Brown University:
$100 million gift to Brown will name Carney Institute for Brain Science, advance discoveries and cures
One of the single largest gifts in University history will drive research into brain and nerve disorders and establish one of the best-endowed brain institutes in the country. Brown University announced that alumnus and Trustee Robert J. Carney and his wife, Nancy D. Carney, have donated $100 million to our brain science institute. Click here to learn more.

Caregivers Journey Conference:
Alzheimer's Association, Rhode Island Chapter
The 8th annual "Caregivers Journey" conference will take place on April 26th, 2018 at the Crowne Plaza in Warwick, RI. Dr. Stephen Salloway, Professor of Neurology and Psychiatry, Alpert Medical School of Brown University and Director of the Memory and Aging Program at Butler Hospital will deliver the conference's keynote address, "Developing Breakthroughs for Alzheimer's: What Rhode Islanders Can Do." The conference is free for caregivers. Click here to learn more.

77WABC Radio:
Joan Hamburg: Joan Hamburg Interviews Dr. Salloway
Joan Hamburg interviews Dr. Stephen Salloway about new treatments and advancements that are being developed and it is something that can change this disease entirely. Click here to learn more.

RI State Plan Announcement:
Lt. Governor McKee, Alzheimer's Association Secure $30K to Update State Plan on Alzheimer's
Lt. Governor McKee announced $30,000 in grants secured by his office and the Rhode Island chapter of the Alzheimer's Association to update the state's five-year plan on Alzheimer's Disease and Related Disorders. Tufts Health Plan Foundation and the Rhode Island Foundation each pledged $15,000 to support the initiative. Click here to learn more.

The Mercury News:
Mark Zuckerberg, Priscilla Chan to fund Stanford award to fight Alzheimer's disease
Facebook founder Mark Zuckerberg and his wife, Priscilla Chan, have launched a new effort with Stanford School of Medicine to fight Alzheimer's disease and other neurodegenerative diseases. Click here to learn more.

Global Alzheimer's Platform (GAP) Foundation's GAP-Net Site Optimization Conference Unites 63 Leading Research Sites to Accelerate Alzheimer's Disease Clinical Trials
The brightest minds in Alzheimer's research are meeting in Las Vegas for the Global Alzheimer's Platform Foundation's GAP-Net Site Optimization Conference from Feb 21 – 23. GAP-Net is a first-of-its-kind network of clinical trial sites collaboratively working to streamline clinical research and drug development for Alzheimer's disease. GAP-Net currently has 63 leading academic and private research site partners throughout North America. Click here to learn more.

Inside One Couple's Experimental Treatment to Battle Alzheimer's Disease
In a multi part series, TIME magazine follows Peter and JoAnn Wooding through their journey to combat Alzheimer's disease. Peter is one of the 2,700 people around the world who are expected to volunteer to test what researchers believe could be the first drug to halt Alzheimer's. Click here to learn more.

Providence Journal:
Brown University receives $56M in gifts to benefit medical research
Brown Chancellor Samuel M. Mencoff and wife Ann S. Mencoff have given Brown University's Warren Alpert Medical School $50 million intended to help transform biomedical research into cures and treatments for disease, the university announced on Thursday. A separate, anonymous $6-million gift will specifically advance scholarship and research into Alzheimer's and other neurodegenerative diseases. Click here to learn more.

The Providence Journal:
New drug to treat Alzheimer's disease under study at Butler Hospital
The clinical trial seeks to assess the safety, tolerability and effectiveness of the experimental drug Tauriel in people with early to mild signs of Alzheimer's, according to the hospital's Memory and Aging Program. Click here to learn more.

Nature Letter:
High Performance Plasma Amyloid-β Biomarkers for Alzheimer's Disease
To facilitate clinical trials of disease-modifying therapies for Alzheimer's disease supportive biomarker information is necessary. The only validated methods for identifying amyloid-β deposition in the brain — the earliest pathological signature of Alzheimer's disease — are PET scans or cerebrospinal tap. Therefore, a minimally-invasive, cost-effective blood-based biomarker is desirable. The results of this paper demonstrate the potential clinical utility of plasma biomarkers in predicting brain amyloid-β burden at an individual level potentially enabling broader clinical access and efficient population screening. Click here to learn more


University of Rhode Island:
Executive Director of URI's Ryan Institute receives prestigious honor from national science peers
Paula Grammas, executive director of the University of Rhode Island's George & Anne Ryan Institute for Neuroscience, has been elected a Fellow of the American Association for the Advancement of Science in recognition of her pioneering research into neurodegenerative conditions, including Alzheimer's disease. Click here to learn more.

Rhode Island Chapter of the Alzheimer's Association:
2018 Keynote Speaker: Stephen P. Salloway, MD, MS
Dr. Stephen Salloway will be the Keynote speaker at this year's Caregiver's Journey Conference which is open to caregivers and professionals who dedicate their lives to caring for people with Alzheimer's disease and related dementia's. The conference will include lectures from renowned experts in the field and breakout sessions to provide tools geared toward carrying out the best practices of providing care. Click here to learn more.

Providence Journal:
Researchers build ‘citizens army' in war against Alzheimer's
Promising new research at Butler Hospital and Brown University begins with a simple swab of the cheek. Dr. Salloway and his team at Butler's Memory and Aging Program are seeking volunteers to enlist in the so-called Generation Study, for men and women age 60 to 75 who are cognitively normal — but may be at risk, depending on their genetic makeup. They would become the latest recruits in Salloway's citizen army — which, when all studies and the Butler prevention registry are counted, now numbers more than 800. Click here to learn more.

WLNE Ch. 6:
Clinical Trial Tests Pill Aimed at Preventing Alzheimer's before it starts
A new medication aimed at stopping Alzheimer's before it even starts is in the works. The drug is being tested through a landmark clinical trial at Butler Hospital in Providence. Click here to learn more.

RI NPR Artscape:
Striking a New Cord, Part 2
"Research shows that learning to use a musical instrument in older age can help protect you against dementia and Alzheimer's disease," said Dr. Jessica Alber, a cognitive neuroscientist at the Butler Hospital Memory and Aging Program in Providence. Click here to learn more.

AARP Bulletin:
Avoid Alzheimer's by Understanding Your Risk Factors
You can take preventive measures to preserve your memories, even if you have the Alzheimer's gene, experts say. Click here to learn more.

National Institute on Aging (NIA):
New National Institutes of Health consortium award to enhance clinical trials for Alzheimer's disease, related dementias.
The National Institutes of Health (NIH) has announced a new clinical trials consortium expected to accelerate and expand studies of therapies in Alzheimer's and related dementias. The Alzheimer's Clinical Trial Consortium (ACTC) will be lead jointly by research teams from the University of Southern California Alzheimer's Therapeutic Research Institute (ATRI), San Diego, Harvard- affiliated Brigham and Women's Hospital and Massachusetts General Hospital, Boston and Mayo Clinic, Rochester, Minnesota.

The ACTC experts and infrastructure will support the design and conduct of trials across the full spectrum of Alzheimer's and related dementias, from prevention initiatives to combination trials for advanced symptomatic stages. The ACTC will also include a Minority Outreach and Recruitment Team that will enhance and support both central and local partnerships with diverse communities, to include and benefit everyone affected by Alzheimer's disease. The consortium currently includes 35 sites in 24 states and the District of Columbia. Click here to learn more.

Providence Journal:
Butler Hospital begins study of drug to slow or prevent Alzheimer's disease
Researchers at Brown University-affiliated Butler Hospital began a clinical trial of a new medication that could slow or prevent Alzheimer's disease among people at genetic risk for the condition. The research group was among the first in the world to start the trial, known as Generation 2, which will be conducted at 185 centers in 25 countries when fully operational. This fight against Alzheimer's, is being led by Dr. Stephen Salloway, chief Alzheimer's researcher at Butler, is sponsored by Novartis Pharmaceuticals in partnership with Amgen and Banner Alzheimer's Institute. Click here to learn more.

New York Times:
What if You Knew Alzheimer's was coming for you?
Twenty-five percent to 50 percent of us will show signs of Alzheimer's by the age of 85. Scientists say they are on the cusp of developing blood tests that could detect the earliest signs of Alzheimer's damage in people in their 40s and 50s who have no obvious symptoms. This would be more cost-effective diagnostic tool as compared to a PET scan and less invasive than a lumbar puncture. It also raises a difficult question for individuals on whether or not they would like to know their genetic risk, how much they would be willing to share with family and friends and how it could affect their insurance and long-term care. Click here to learn more.

WPRI Ch. 12:
Doctor: Bill Gates donation could have huge impact on research
Dr. Danielle Goldfarb discusses Bill Gates donation announcement of $50 million to studying Alzheimer's and the impact it will have on dementia research. She expects Gates' donation to the Dementia Discovery Fund to have a huge impact on her field, as well as, all those touched by the disease. One of Butler Hospital's current research initiatives is an Alzheimer's Prevention Registry which invites Rhode Islanders 55 and older who are interested in getting involved to join and see if they are eligible for any enrolling clinical trials. Click here to learn more.

gatesnotes - The Blog of Bill Gates:
"Bill Gates is Digging Deep into Alzheimer's"
Microsoft founder and philanthropist Bill Gates announced his commitment to finding a breakthrough treatment for Alzheimer's disease through a $50 million investment in the Dementia Discovery Fund. This private fund will help support startups who are exploring less mainstream approaches to treating dementia while complementing the work of major pharmaceuticals. Click here to read the full article and view the video.

Brown Daily Herald:
Alzheimer's study may provide methods of prevention, economical diagnosis Brown University professors conducting research at Butler Hospital and RI Hospital are looking to see if a retinal scan can be used to help identify people with amyloid plaque build-up, which has been linked to an increased risk for Alzheimer's disease. In combination with a PET scans and the use of investigational medication, there may be hope in the future that memory loss can not only be delayed, but identified earlier using a more accessible test that's not as cost-prohibitive.

Brown University:
Researchers seek to catch Alzheimer's early by peeking into the eyes
Research spanning the academic-medical partnership among Brown University, Rhode Island Hospital and Butler Hospital is advancing the possibility that the retinas will give doctors a way to identify Alzheimer's disease risk long before symptoms begin. Mark Wolff wanted to know. To him, the thought of suffering through Alzheimer's disease the way his father did — without knowing, and without his family knowing, what he was up against until late in its progression— is worse than learning, even while he's still perfectly healthy, that a possible precursor of the disease has gained a toehold. Learn more about Mark's experience and about the collaboration between the research teams at Butler Hospital and Brown University.

WJAR Ch. 10 - Health Check:
Alzheimer's Disease Prevention Trial
If you could find out you were at risk for the memory robbing disease Alzheimer's would you want to know? There is a way to find out, by taking part in Alzheimer's prevention trials currently going on in our area. Elaine and Raymond Theriault have been married for 51 years. Raymond, an army veteran, Elaine, a retired nurse have two kids and two grandkids. Both are looking forward to many more years together and memories. And that's why they're here at Butler Hospital's Memory and Aging Program. Learn more about their experiences participating in our clinical trials.

WJAR Ch. 10 – Health Check:
Eye Exam for Alzheimer's Disease
Susan Sullivan continues to be a "citizen of science" by volunteering for her third clinical trial with the Memory and Aging Program. Barbara Morse Sullivan reports on how this trial uses a special retinal scan to detect amyloid proteins. If validated, the retinal scan may be a more cost effective diagnostic exam to identify people at risk for developing Alzheimer's disease in the future.

Providence Journal -
RI Seeks New Way to Diagnosis, Prevent Alzheimer's Disease
Butler's Memory and Aging Program enrolled its first participant in a retinal imaging trial that's studying whether an investigational medication can lower amyloid plaques in the brain as well as in the retina for those at risk of developing the disease. If successful, retinal imaging may have the ability to be a more cost-effective way to detect and monitor AD risk and prevention.

ABC 6 News (WLNE-TV, Providence) - Brown University Alzheimer's Study May Lead to Early Detection

Congress Delivers Historic Alzheimer's Research Funding Increase for Second Consecutive Year

Congress will pass to an increase of $400 million to Alzheimer's research funding at the National Institute of Health (NIH) for the 2017 fiscal year budget, bringing the total funding to approximately $1.4 billion. This is the second year in a row funding has grown. This will help keep advancing the primary goal of National Plan to Address Alzheimer's -- finding an effective treatment and prevent AD by 2025 -- helping keep hope alive for the 5 million Americans and their 15 million caregivers who are affected by this devastating disease. Read the Alzheimer's Association's press release for more details.

NBC 10 Healthcheck:
Barbara Morse covers a new prevention trial called Generations. Watch the Video

"The New Offensive on Alzheimer's Disease: Stop It Before It Starts"
In a recently published comprehensive article, Newsweek took stock of the current state of affairs for Alzheimer's disease (AD). The cover story for the February 24 edition, the article delves into the far-reaching effects and implications of the disease, including how it will continue to wreak havoc on the global community, both from a health and wellness perspective, as well as financially. Though finding a cure for AD has held a prominent focus in the research and pharmaceutical fields, the clinical trials testing treatments for AD have a more than 99 percent failure rate. Currently, researchers have switched their attention to investigating preventions, with one new prevention study called EARLY, administering a targeted drug to people who are healthy but have elevated amyloid in their brains, which indicates an increased risk of developing AD.

Facing Dementia is a five part television series airing on Channel NewsAsia, an English Language TV news channel based in Singapore. The series follows several families as they navigate through diagnosis, caregiving and treatment of loved ones affected by different types of dementia. In this episode, What the Future Holds, Dr. Stephen Salloway discusses the current and future state of Alzheimer's research as scientists worldwide work together to find a cure. We're also introduced to two families from the Memory and Aging Program that are participating in different clinical trials, but that have similar goals of slowing down or preventing Alzheimer's disease.

Washington University School of Medicine in St. Louis -
"Landmark Alzheimer's prevention trial to evaluate third drug"
The Washington University School of Medicine in St. Louis is collaborating with Janssen Research & Development to bring a third investigational drug into worldwide clinical trial testing that could potentially be used as a treatment in preventing Alzheimer's disease. It will become part of a trio of investigational drugs used in the Dominantly Inherited Alzheimer's Network Trial Unit (DIAN-TU) study. Dr. Stephen Salloway is a Project Arm Leader for DIAN-TU, which is being conducted at Butler's Memory and Aging Program.

The Providence Journal -
"In war on Alzheimer's, R.I.'s Butler Hospital is leading the charge"
This feature story first seen on the front page of the journal, looks at the current affairs in the war on Alzheimer's disease, and ranks Dr. Stephen Salloway, director of Butler's Memory and Aging Program, as a general. The in-depth coverage includes articles and accompanying photos and videos that delve into the variety of efforts of Butler's Memory and Aging Program. A broad spectrum of clinical trials and initiatives that bring the program into collaborations both locally and globally, speak to the committed effort within the Memory and Aging Program to lead a charge toward finding effective treatments for Alzheimer's.

Also reported by:

The Providence Journal EDITORIAL – "Editorial: R.I. battles Alzheimer's"

NBC Channel 10 – "Health Check: Alzheimer's disease treatment"

ABC Channel 6 – "A breakthrough clinical trial, giving hope to patients with Alzheimer's"

TIME - "An Alzheimer's Drug Shows Serious Promise"

Science News – "New Alzheimer's drug shows promise in small trial"

Huffington Post – "New Drug Clears Abnormal Brain Proteins Tied To Alzheimer's"

Fox News – "Drug shows promise in reducing abnormal brain proteins linked to Alzheimer's"

Brown University – "Rhode Island's role in promising new Alzheimer's results"

Scientific American – "Alzheimer's Drug Shows Promise in Small Trial"

Science – "Alzheimer's trial supports β amyloid origin of disease"

Toronto Star – "High hopes new drug could be a ‘game changer' against long-incurable Alzheimer's" W Radio (en español) – "Fármaco para el Alzhéimer va a estar disponible a la venta en unos años: Stephen Salloway"

08/11/16 -
"Coming to a Center New You: GAP & EPAD to Revamp Alzheimer's Trials"
This three-part story discusses how two of the largest Alzheimer's disease (AD) reform initiatives, GAP & EPAD, are leading the worldwide effort to revamp how clinical trials recruit potential participants and the plan to evaluate more AD investigational drugs in a more timely and cost effective manner. Their integrated approach is focused on streamlining communication and procedures among pharmaceutical companies, academics and even individual governments.

The Today Show -
"New Alzheimer's Disease Drug May Help People at Risk"
Dr. Reisa Sperling, lead investigator for the A4 study in Boston, talks with Maria Shriver about how the study is investigating a new drug aimed at preventing people from developing a buildup of amyloid protein in the brain, which is associated with Alzheimer's disease.

WJAR Channel 10 News -
"Alzheimer's disease prevention research" Dr. Stephen Salloway discusses a new partnership with the Brain Health Registry and how it can help direct people to participate in prevention trials, such as GeneMatch, especially if there is a family history of Alzheimer's like Paul Cote's family.

WJAR Channel 10 News -
"Alzheimer's end-of-life study"
One of the program's most highly altruistic trials, the A16 Autopsy Tau Imaging trial, is currently enrolling with the goal of developing a new diagnostic brain scan.

Convergence RI -
"Rhode Island emerges as a key hub of Alzheimer's research"
Dr. Stephen Salloway discusses how public-private collaborations are the future for treating and preventing Alzheimer's by 2025.

Providence Journal -
"Help Defeat Alzheimer's"
Butler and Rhode Island Hospitals are leading the state in a nationwide study that aims to delay or prevent Alzheimer's disease in America's aging population.

Butler Enrolls First Participant in National Landmark Alzheimer's Study Designed to prevent memory loss, the A4 Study" (Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease Study) is seeking to enroll 1,000 healthy adults who are at risk for developing Alzheimer's disease but show no outward signs of the disease. Press release

WJAR Channel 10 News -
"Alzheimer's Disease Prevention Trial"
NBC's news affiliate covers the story of Peter Bristol as he becomes the first patient to receive treatment in the A4 Study being conducted at Butler Hospital in partnership with National Institutes of Health (NIH) and Eli Lilly.

Rhode Island Public Radio -
"Butler Kicks Off Alzheimer's Prevention Trial" Butler Hospital begins enrollment of a national landmark trial, the A4 Study, that tests a specific drug's potential to help prevent Alzheimer's disease.

Deep Brain Stimulation Surgery for Alzheimer's Disease Geraldine Paquin is about to embark on uncharted waters undergoing deep brain stimulation (DBS) for Alzheimer's disease.

Learn more DBS for Alzheimer's about from WJAR 10's Barbara Morse Silva on Health Check 10.

New Deep Brain Stimulation Study for Alzheimer's Disease Butler Hospital's Memory & Aging Program, in collaboration with Rhode Island Hospital, is testing deep brain stimulation for Alzheimer's disease.

Subscribe to our monthly Memory Matters